Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $20
Climb Bio Inc CLYM
$11.90
▼ -1.49%
($-0.18)
🔥 High Short Interest
🗓️ Earnings Next Week
Open
$12.20
Prev Close
$12.08
Day Range
$11.45 – $12.25
52W Range
$1.36 – $14.42
Market Cap
$681.43M
Beta
0.11
EPS (TTM)
$-0.78
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-08-10 |
| Shares Out. | 57,260,000 |
| Website | climbbio.com/ ↗ |
| Phone | 18668572596 |
| Employees | 29 |
| Net Income | -$13.7M |
| Free Cash Flow | -$53.5M |
| Total Assets | $152.4M |
| Total Liabilities | $4.3M |
| Equity | $148.1M |
About Climb Bio Inc
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
Climb Bio Inc is a publicly traded company under the ticker symbol CLYM on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
21 analysts (2026-07-01)